Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia

Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia

# Introduction In Saudi Arabia, patients with metastatic colorectal cancer (mCRC) with wild-type RAS mutations may be treated with either cetuximab plus chemotherapy (CET + CT) or panitumumab plus chemotherapy (PAN + CT), which are epidermal growth factor receptor (EGFR) antibodies. This study calcu...

Full description

Saved in:
Bibliographic Details
Main Authors: Gihan Elsisi, Hana Abdul Kareem, Abdelaziz Alaseiri, Abdullah Alsharm, Mohammed Algarni, Hajer Al-Mudaiheem, Fouad Alnagar, Hazem Lotfy, Mohamed Ouda, Ahmed Elshehri
Format: Article
Language:English
Published: Columbia Data Analytics, LLC 2025-03-01
Series:Journal of Health Economics and Outcomes Research
Online Access:https://doi.org/10.36469/001c.130878
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items